The complement system is an integral part of the innate immune response. Given its important role in many human disorders, complement activation measurements are important in a wide range of applications.
The individual complement profile of a patient gives valuable information of the course and severity of a disease, and as a consequence, complement assays have evolved as essential tools not only in initial diagnosis but for following disease progression and monitoring complement-targeted therapies.
To determine whether deficiencies, overactivation and/or dysregulation in the complement system are causing, or contributing to, a person's disease or condition activity biomarkers can be used, and these types of tools have become increasingly available in routine clinical use.
The complement system is an integral part of the innate immune response. Given its important role in many human disorders, complement activation measurements are important in a wide range of applications.
The individual complement profile of a patient gives valuable information of the course and severity of a disease, and as a consequence, complement assays have evolved as essential tools not only in initial diagnosis but for following disease progression and monitoring complement-targeted therapies.
To determine whether deficiencies, overactivation and/or dysregulation in the complement system are causing, or contributing to, a person's disease or condition activity biomarkers can be used, and these types of tools have become increasingly available in routine clinical use.
Svar has over 15 years’ experience of complement system assay development. Our complement system assays have been developed by our experienced scientists in close collaboration with key opinion leaders, to yield sensitive, reliable and easy-to-use products for the exploration of most aspects of the complement system.
The Svar Complement activity biomarkers give valuable intelligence in several situations where one might suspect that complement activation plays a role in the disorder. They are developed to target the unique neoepitopes only presented at the complement component or complex when activated.
Take advantage of our complement expertise and let us guide you on the Complement Pathway!